Vol. 6 No. 8 (2026): August
Reimbursement Reviews

Beclomethasone Dipropionate, Glycopyrronium (as Bromide), and Formoterol Fumarate Dihydrate (Trimbow)

decorative image of the issue cover

Published August 12, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Beclomethasone dipropionate, glycopyrronium (as bromide) and formoterol fumarate dihydrate (PrTRIMBOW™), 100/10/6* μg, pressurized inhalation solution, oral inhalation
  • Indication: TRIMBOW (beclomethasone dipropionate, glycopyrronium (as bromide) and formoterol fumarate dihydrate) pressurized inhalation solution is a combination of an ICS, a LAMA, and a LABA, indicated in adult patients who are not adequately treated by a combination of an ICS and a LABA or a combination of a LABA and a LAMA:
    • for the long-term, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema;
    • to reduce exacerbations of COPD in patients with a history of exacerbations